Plasma extracellular vesicle microRNA profiling and the identification of a diagnostic signature for stage I lung adenocarcinoma
Quick Facts
- Publication title: Plasma extracellular vesicle microRNA profiling and the identification of a diagnostic signature for stage I lung adenocarcinoma
- Journal: CANCER SCI
- Year: 2021
- DOI: 10.1111/cas.15222
- PMID/PMCID: 34837453; PMC8819331
Research overview
This study examined the profile of plasma extracellular vesicle (EV)-delivered microRNAs (miRNAs) in patients with invasive stage I LUAD. This study examined the profile of plasma extracellular vesicle (EV)-delivered microRNAs (miRNAs) in patients with invasive stage I LUAD.
Key findings
At present, there is no effective noninvasive method for the accurate diagnosis of early-stage lung adenocarcinoma (LUAD).
This study examined the profile of plasma extracellular vesicle (EV)-delivered microRNAs (miRNAs) in patients with invasive stage I LUAD.
In this study, a total of 460 participants were enrolled, including 254 patients with LUAD, 76 patients with benign pulmonary nodules (BPNs), and 130 healthy control patients (HCs).
miRNA sequencing was used to analyze the EV miRNA profile of the patient plasma samples (n = 150).
Echo Biotech Role
Echo Biotech contributed whole-transcriptome sequencing, miRNA profiling/sequencing and bioinformatic analysis.
Related platforms: Exoomics®
Related services and capabilities: EV miRNA Profiling / Sequencing, EV Whole-Transcriptome Sequencing
References
Original publication: Plasma extracellular vesicle microRNA profiling and the identification of a diagnostic signature for stage I lung adenocarcinoma CANCER SCI. 2021. DOI: 10.1111/cas.15222. PMID/PMCID: 34837453; PMC8819331.